[
    {
        "title": "**A. Preparation of splenic DCs**",
        "body": [
            {
                "title": "1.",
                "body": "Sacrifice C57/BL6 mice."
            }
        ]
    },
    {
        "title": "**Note**",
        "body": [
            ". All experiments involving animals must be carried out according to institutional and national guidelines.",
            {
                "title": "2.",
                "body": "Extract spleens and place them in a Petri dish."
            },
            {
                "title": "3.",
                "body": "Using tweezers to hold the spleen. Employ a syringe to inject into this organ PBS/EDTA solution. Collect the fluid that exits the spleens. Inject until the colour of the organ becomes clearer. This treatment facilitates the subsequent disaggregation of the spleen."
            },
            {
                "title": "4.",
                "body": "Place the spleens on a cell strainer and, while PBS/EDTA solution is poured over the spleen and strainer, use the plunger of a syringe to disaggregate the spleens."
            },
            {
                "title": "5.",
                "body": [
                    "Collect the cellular suspension with splenic cells and centrifuge at 1500 rpm \\(453",
                    {
                        "title": "g)",
                        "body": "for 10 min at 4ºC."
                    }
                ]
            },
            {
                "title": "6.",
                "body": "Resuspend the cellular pellet in cold MACS buffer and add the required volume of anti-CD11c Miltenyi magnetic MicroBeads \\(25 µl per 10<sup>8</sup> DCs)."
            },
            {
                "title": "7.",
                "body": "Incubate for 15 min at 4ºC."
            },
            {
                "title": "8.",
                "body": "Add cold MACS buffer up to a volume of 3 ml."
            },
            {
                "title": "9.",
                "body": "Equilibrate Miltenyi LS Column by passing 3 ml of MACS buffer. Apply cell suspension onto the equilibrated LS Column."
            },
            {
                "title": "10.",
                "body": "Collect unlabeled cells that pass through. Wash LS Column three times with 3 ml of buffer. This is the unlabeled cell fraction."
            },
            {
                "title": "11.",
                "body": "Remove the Column from the separator and place it in a new collection tube."
            },
            {
                "title": "12.",
                "body": "Pipette 5 ml of MACS buffer onto the LS Column and flush out the fraction with the magnetically labelled cells by applying a plunger. The cell fraction obtained is the DC fraction."
            }
        ]
    },
    {
        "title": "**B. Labelling and injection of DCs**",
        "body": []
    },
    {
        "title": "**Note**",
        "body": [
            ". The protocol indicated  below describes largely the labeling of  DCs with CMFDA \\(subsequent injection of mice with SR-FLIVO). The protocol  is exactly the same if the DCs are labeled with SNARF1, with the difference that mice should be then injected with FAM-FLIVO.",
            {
                "title": "1.",
                "body": "Add 5 µM of CMFDA \\(dilute 1:1000 CMFDA stock solution) to the DCs obtained after the elution  from the LS Columns."
            },
            {
                "title": "2.",
                "body": "Incubate for 40 min at 37ºC."
            },
            {
                "title": "3.",
                "body": "Add 2 volumes of cold complete medium to quench staining and incubate 5 min in ice."
            },
            {
                "title": "4.",
                "body": [
                    "Centrifuge twice 5 min at 1000 rpm \\(201",
                    {
                        "title": "g)",
                        "body": "at 4ºC. Collect the pellet and suspend in RPMI at a concentration of 20-40x10<sup>6</sup> DCs/ml."
                    }
                ]
            },
            {
                "title": "5.",
                "body": "Inject 50 µl of suspension of DCs in RPMI \\(1-2x10<sup>6</sup> DCs) along with LPS \\(1µg/ml) in each footpad."
            }
        ]
    },
    {
        "title": "**C. Intravenous injection of FLIVO**",
        "body": [
            {
                "title": "1.",
                "body": "Ensure in prior experiments that the labelled DCs have reached the LN before injecting FLIVO<sup>TM</sup>. Use a U-100 insulin syringe to inject  intravenously each animal with 40 µl of stock solution of FLIVO<sup>TM</sup> \\(0.2 mg/ml), i.e. with 8 µg of FLIVO. \\(Inject Red SR-FLIVO<sup>TM</sup> or Green FAM-FLIVO<sup>TM</sup> if CMFDA- or SNARF1-labeled DCs, respectively, were previously injected)."
            }
        ]
    },
    {
        "title": "**D. Extraction and preparation of the samples of PLN**",
        "body": [
            {
                "title": "1.",
                "body": "Sacrifice the animals. Isolate the PLNs and, under a magnification glass, trim them carefully free of fat. Fix the PLNs with paraformaldehyde for at least 30 min and then immerse them in PBS."
            },
            {
                "title": "2.",
                "body": "Use a razor blade and a magnification grass to cut transversally the PLN along the longest axis of this organ in two halves."
            },
            {
                "title": "3.",
                "body": "Mount the two halves of the PLNs between two square coverslips. To mount the PLNs prepare the following setting. Make an approximately 0.5 mm thick layer composed of two sided tape \\(Scotch). Perforate with a punch a small circular hole with a diameter large enough to fit the two halves of the PLNs. Stick the two sided tape 0.5 mm thick layer onto one of coverslips. Carefully deposit into the small circular hole in the cellotape layer the two halves of the PLNs. Immerse the two pieces of PLNs in fluorescence mounting medium. Finally, taking care to avoid air bubbles, seal the sandwich that include the LNs, with the second glass coverslip."
            }
        ]
    },
    {
        "title": "**E. Visualization of the DCs in the LN with two photon optics**",
        "body": [
            {
                "title": "1.",
                "body": "Analyze the PLNs under the two photon microscope using a 20×magnification oil-immersion objective \\(1.20 NA) in a Leica confocal inverted microscope. Optimal two-photon excitation of the three fluorochromes is achieved at 856 nm wavelength and spectral detection is at 510-540 nm \\(for CMFDA and FAM-FLIVO) and 560-600 nm \\(for SNARF1 and SR-FLIVO). Detector slits are configured to minimize crosstalk between channels. LNs are thoroughly scanned from both sides of the coverslip up to a depth of 200-300 μm with a z spacing of 2 μm."
            }
        ]
    },
    {
        "title": "**F. Analysis of the presence of SR-FLIVO in DCs by two photon microscopy**",
        "body": [
            {
                "title": "1.",
                "body": "Examine two-photon microscopy optical section stacks obtained from the analysis of the LN for the presence of FLIVO staining using the Leica Confocal Software \\(LCS) \\(see"
            }
        ]
    },
    {
        "title": "**Supplementary Fig. 5 online**",
        "body": [
            "in Ref 7).",
            {
                "title": "2.",
                "body": "To quantify the amount of FLIVO incorporated by the cells labeled with the fluorescent cell tracker probes \\(CMFDA or SNARF1), we use the LCS profile quantification tool. Several lineal Regions of Interest \\(ROI) are traced in each cell to be analyzed. Subsequently, graphs with the intensity profiles of the SNARF1/FAM-FLIVO<sup>TM</sup> or CMFDA/SR- FLIVO<sup>TM</sup> pair intensity are obtained. It is important to check for leakage between SR-FLIVO<sup>TM</sup> and CMFDA channels."
            },
            {
                "title": "3.",
                "body": "The value of Maximum Amplitude of the SR-FLIVO, measured automatically by the LCS, provides an index of the incorporation of FLIVO and, consequently, information on the degree of apoptosis of the DC analysed \\(see below). To this value it should be subtracted the value of FLIVO channel background in the field where the cell is positioned \\(see"
            }
        ]
    },
    {
        "title": "**Supplementary Fig. 5 online**",
        "body": ", Ref 7)."
    },
    {
        "title": "**G. Analysis of apoptotic DCs in the LN**",
        "body": [
            {
                "title": "1.",
                "body": "A calibration for each batch of FLIVO<sup>TM</sup> is required to assess the value of the Maximum Amplitude of the FLIVO channel that marks the limit between non-apoptotic and apoptotic DCs. This limit value is determined in prior _in vitro_ experiments where the ability of FLIVO and Hoechst to stain apoptotic DCs is compared. In our experiments, non-apoptotic DCs, determined according to Hoechst staining, displayed a Maximum Amplitude of the SR-FLIVO channel equal or lower than 30 \\(see"
            }
        ]
    },
    {
        "title": "**Supplementary figures 4 and 5 online**",
        "body": [
            ", in Ref.",
            {
                "title": "7).",
                "body": "Thus, we considered the DCs that have a Maximum Amplitude of the SR-FLIVO above this value as apoptotic."
            },
            {
                "title": "2.",
                "body": "This limit value may change with a different batch of FLIVO, hence, as indicated above, calibration is required every time the batch of FLIVO is changed. We obtained similar results either measuring the values of maximum intensities of SR-FLIVO or the ratio Maximum Amplitude SR-FLIVO over the Maximum Amplitude CMFDA, implying negligible leakage from the CMFDA channel. In case of doubt on the possibility of leakage, it is probably safer to represent the data as a ratio."
            },
            {
                "title": "3.",
                "body": "In studies to ascertain whether a treatment increases or reduces the percentage of apoptotic DCs in the LNs, if the absolute value of the percentage of live DCs is not required, it is possible to analyse the results just by comparing the average value of the Maximum Amplitude of FLIVO in control and treated animals."
            }
        ]
    }
]